Ravasio, R., Tiseo, M., Pradelli, L., Bellone, M., Gervasi, A., & Coffani, M. (2019). Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. Global and Regional Health Technology Assessment, 6(1). https://doi.org/10.33393/grhta.2019.462